Morphotek in evaluation agreement with University Hospital
25 January 2009
Morphotek, Inc., a subsidiary of Eisai Corporation of North America,
has announced the signing of an evaluation agreement with the University
Hospital Heidelberg and its Technology Transfer Office, Germany to
advance the company's efforts in the discovery and development of
therapeutic antibodies in oncology.
The agreement provides for a research grant to the University
Hospital/National Center for Tumor Diseases (NCT) and for use by
Morphotek of biological materials to generate and validate therapeutic
monoclonal antibodies to oncology targets selected by Morphotek.
“We are very pleased to be collaborating with one of the world’s
leading research and clinical centers in oncology,” said Nicholas
Nicolaides, PhD, President and CEO of Morphotek.
“This research program offers Morphotek unique clinical materials to
generate and validate potential therapeutic antibodies using our
MORPHODOMA® technologies and will enable us to advance our goal of
discovering and developing novel monoclonal antibody therapeutics. The
clinical group at NCT is dedicated to bringing new therapies to treat
patients with cancer, and we look forward to collaborating with them to
discover new experimental medicines with potential to treat patients
with various cancers.”
Bookmark this page